Showing 61-70 of 354 grants

Title Institution Researcher Program Duration Total Award Amount
CD40L-Targeting Small Molecules as Novel Immunotherapies in Islet Cell Transplantation and T1D Prevention University of Miami Peter Buchwald Cures 01-October-2026 to 30-September-2027 $250,000.00
Enhance β-Cell Replacement Therapies via Localized Immune Modulation Using DIANA Nanocarriers University of Miami Peter Buchwald Cures 01-September-2023 to 31-August-2026 $900,000.00
Low-dose IL-2 and anti-CD40L as a therapy for type 1 diabetes University of Miami Thomas Malek Cures 01-June-2024 to 31-May-2027 $927,000.00
mIL-2/CD25 fusion protein and BTK inhibitor combination therapy for T1D University of Miami Wasif Khan Cures 01-May-2023 to 30-April-2027 $974,996.00
A Cure for Type 1 Diabetes University of Massachusetts Medical School David Harlan Cures 01-October-2025 to 30-September-2029 $16,000,000.00
In vivo interactions and trafficking of islet antigen-specific human effector T cells and Tregs University of Massachusetts Medical School Michael Brehm Cures 01-November-2024 to 31-October-2027 $825,000.00
Interrogation of FBR immunity using novel humanized mice University of Massachusetts Medical School Michael Brehm Cures 01-October-2026 to 30-September-2027 $300,000.00
Artificial Intelligence-driven redesign of beta cell regulatory logic for resilience to inflammation University of Massachusetts Medical School Rene Maehr Cures 01-April-2026 to 31-March-2027 $199,999.88
Defining the target product profile of intra-lymph node depots as a durable antigen-specific immunotherapy for T1D University of Maryland Christopher Jewell Cures 01-April-2026 to 31-March-2029 $1,199,997.36
NKG2D Signaling as a Critical Modulator of Autoreactive CD8⁺ T Cell Differentiation and β Cell Destruction in Type 1 Diabetes University of Kansas Medical Center Research Institute, Inc. Ambika Dudhate Cures 01-March-2026 to 28-February-2029 $274,010.00